<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01012921</url>
  </required_header>
  <id_info>
    <org_study_id>CR 07/07</org_study_id>
    <nct_id>NCT01012921</nct_id>
  </id_info>
  <brief_title>Comparison of a PEG Membrane and a Collagen Membrane for the Treatment of Bone Dehiscence Defects at Bone Level Implants</brief_title>
  <official_title>Straumann® MembraGel Comparison of a PEG Membrane and a Collagen Membrane for the Treatment of Bone Dehiscence Defects at Bone Level Implants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Straumann AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Straumann AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to test in a randomized comparative study the performance of
      Straumann® MembraGel (PEG Membrane) to act as a barrier for guided bone regeneration compared
      to that of a standard collagen membrane (BioGide®) in the bone regeneration around Straumann®
      SLActive bone level titanium implants.

      Furthermore the clinical evaluation and comparison of complementary parameters describing the
      bony and soft tissue environments at the surgical sites during the study period to evaluate
      effectiveness and performance of the membranes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the primary endpoint of the study - 6 month post-operative - the vertical bone gain will
      be measured for changes.

      The changes will be evaluated by measuring the distance between the implant shoulder and the
      first visible bone contact on the implant. The measurement will be taken on the medial and
      distal aspect on the implant at site of interest. Measurements will take into account
      distortion based on changes on the radiograph from the true dimension of the implant.

      Intra-oral photographs will be taken at each study visit to document the initial appearance
      of the soft tissue and the subsequent healing of the soft tissue post-implant placement. The
      photographs will be taken buccal and occlusial at study site of interest.

      The physical appearance of soft tissue (form, colour, tissue biotype, surface aspect) will be
      clinically assessed by visual inspection.

      In addition changes in the high of the keratinized gingiva will be assessed in mm. This will
      be measured mid-crestal in buccal direction to the mucogingival border by a periodontal
      probe.

      Changes in gingival recession will be measured at the implant leading visit and the yearly
      follow-up visit 18, 30 and 42 month post surgery. The distance between the margin of the
      gingiva and the edge of the crown will be assessed at accessible buccal, palatal, distal and
      medial sites.

      A measurement of vertical defect height will be performed evaluating the distance of the
      implant shoulder to the first bone to implant contact at surgery visit and 6-month later.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Bone Fill Was Assessed at 6 Months After Regenerative Therapy.</measure>
    <time_frame>Assessed at 6 months reported</time_frame>
    <description>Change between baseline (regenerative therapy) and the 6 months timepoint is reported.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Degeneration; Bone</condition>
  <arm_group>
    <arm_group_label>Bio-Gide® membrane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bio-Gide® membrane This is a biodegradable bilayer membrane for bone and tissue regeneration. It has a natural collagen structure and is of porcine origin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MembraGel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MembraGel The Straumann membrane is a synthetic degradable barrier membrane</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>barrier membrane</intervention_name>
    <description>The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).</description>
    <arm_group_label>Bio-Gide® membrane</arm_group_label>
    <arm_group_label>MembraGel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MembraGel</intervention_name>
    <description>Device application at surgery</description>
    <arm_group_label>MembraGel</arm_group_label>
    <other_name>Straumann® MembraGel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bio-Gide® membrane</intervention_name>
    <description>Device application at surgery</description>
    <arm_group_label>Bio-Gide® membrane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have voluntarily signed the informed consent form before any study
             related action

          -  Males and females must be at least 18 years of age and not more than 80 year old.

          -  Have at least one missing tooth in the posterior mandible or maxilla in quadrant 1, 2,
             3, 4 (FDI positions 4-7), requiring one or more dental implants.

          -  Partially edentulous patients and patients in need of a fixed dental prosthesis

          -  The tooth at the implant site(s) must have been extracted or lost at least 6 weeks
             before the date of implantation.

          -  Bone defect(s) must be present with a vertical dimension greater than or equal to 3 mm
             at the foreseen GBR site measured after dental implant placement.

          -  Full mouth bleeding on Probing (FMBoP) and full mouth plaque score (FMPI) are both
             lower or equal than 25%

          -  Patients must be committed to the study.

        Exclusion Criteria:

          -  Presence of conditions requiring chronic routine prophylactic use of antibiotics
             (e.g., history of rheumatic heart disease, bacterial endocarditis, cardiac valvular
             anomalies, prosthetic joint replacements)

          -  Major systemic diseases

          -  Medical conditions requiring prolonged use of steroids

          -  Use of Bisphosphonate intravenously

          -  Current pregnancy or breastfeeding women

          -  Physical or mental handicaps that would interfere with the ability to perform adequate
             oral hygiene

          -  Alcoholism or chronically drug abuse

          -  Immunocompromised patients

          -  Patients who smoke more than 10 cigarettes per day or cigar equivalents, or who chew
             tobacco

          -  Conditions or circumstances, in the opinion of the investigator, which would prevent
             completion of study participation or interfere with analysis of study results, such as
             history of non-compliance, or unreliability.

        Local exclusion criteria

          -  Local inflammation, including untreated periodontitis

          -  Regenerative treatment necessary adjacent to the planned study site of interest

          -  Mucosal diseases or oral lesions

          -  History of local irradiation therapy

          -  Severe bruxing or clenching habits

          -  Persistent intraoral infection

          -  Patients with inadequate oral hygiene or unmotivated for adequate home care

          -  Previous GBR or GTR treatment at the implant site

          -  Lack of primary stability of the dental implant at site of interest. In this instance
             the patient must be withdrawn and the patient treated accordingly (exclusion criteria
             at surgery)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Haemmerle, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Zürich, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catholic University Leuven School of Dentistry, Oral Pathology &amp; Maxillo-facial Surgery</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite</name>
      <address>
        <city>Berlin</city>
        <zip>14179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1088</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastman Hospital</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Mariano Sanz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Blanco Ramos</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15701</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gävle Hospital</name>
      <address>
        <city>Gävle</city>
        <zip>80187</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2009</study_first_submitted>
  <study_first_submitted_qc>November 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2009</study_first_posted>
  <results_first_submitted>December 21, 2016</results_first_submitted>
  <results_first_submitted_qc>May 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 2, 2018</results_first_posted>
  <last_update_submitted>May 29, 2017</last_update_submitted>
  <last_update_submitted_qc>May 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GBR</keyword>
  <keyword>GTR</keyword>
  <keyword>Dental Implant surgery</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bio-Gide® Membrane</title>
          <description>Bio-Gide® membrane This is a biodegradable bilayer membrane for bone and tissue regeneration. It has a natural collagen structure and is of porcine origin
barrier membrane: The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
Bio-Gide® membrane: Device application at surgery</description>
        </group>
        <group group_id="P2">
          <title>MembraGel</title>
          <description>MembraGel The Straumann membrane is a synthetic degradable barrier membrane
barrier membrane: The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
MembraGel: Device application at surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis population is PP</population>
      <group_list>
        <group group_id="B1">
          <title>Bio-Gide® Membrane</title>
          <description>Bio-Gide® membrane This is a biodegradable bilayer membrane for bone and tissue regeneration. It has a natural collagen structure and is of porcine origin
barrier membrane: The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
Bio-Gide® membrane: Device application at surgery</description>
        </group>
        <group group_id="B2">
          <title>MembraGel</title>
          <description>MembraGel The Straumann membrane is a synthetic degradable barrier membrane
barrier membrane: The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
MembraGel: Device application at surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.1" spread="14.7"/>
                    <measurement group_id="B2" value="50.6" spread="14.0"/>
                    <measurement group_id="B3" value="49.8" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Bone Fill Was Assessed at 6 Months After Regenerative Therapy.</title>
        <description>Change between baseline (regenerative therapy) and the 6 months timepoint is reported.</description>
        <time_frame>Assessed at 6 months reported</time_frame>
        <population>PP</population>
        <group_list>
          <group group_id="O1">
            <title>Bio-Gide® Membrane</title>
            <description>Bio-Gide® membrane This is a biodegradable bilayer membrane for bone and tissue regeneration. It has a natural collagen structure and is of porcine origin
barrier membrane: The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
Bio-Gide® membrane: Device application at surgery</description>
          </group>
          <group group_id="O2">
            <title>MembraGel</title>
            <description>MembraGel The Straumann membrane is a synthetic degradable barrier membrane
barrier membrane: The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
MembraGel: Device application at surgery</description>
          </group>
        </group_list>
        <measure>
          <title>The Bone Fill Was Assessed at 6 Months After Regenerative Therapy.</title>
          <description>Change between baseline (regenerative therapy) and the 6 months timepoint is reported.</description>
          <population>PP</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="2.1"/>
                    <measurement group_id="O2" value="2.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bio-Gide® Membrane</title>
          <description>Bio-Gide® membrane This is a biodegradable bilayer membrane for bone and tissue regeneration. It has a natural collagen structure and is of porcine origin
barrier membrane: The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
Bio-Gide® membrane: Device application at surgery</description>
        </group>
        <group group_id="E2">
          <title>MembraGel</title>
          <description>MembraGel The Straumann membrane is a synthetic degradable barrier membrane
barrier membrane: The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
MembraGel: Device application at surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral hemorrhagic infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lack of osseointegration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Delayed epithelisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Julia Dorn</name_or_title>
      <organization>Institut Straumann AG</organization>
      <phone>0041619651111</phone>
      <email>julia.dorn@straumann.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

